Ketone Production With Acute Caffeine Intake

Healthy Adults Clinical Trial

Official title:

Stimulate the Ketogenesis by Using a Caffeine Supplement

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02694601
• Other study ID #: 2014-441
• Status: Completed
• Phase: N/A
• Start date: January 2014
• Est. completion date: June 2015

Study information

• Verified date: July 2023
• Source: Université de Sherbrooke
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Evaluate the effect of a caffeine supplement on the stimulation of lipolysis and the production of ketones in healthy adults (N=10).

Description:

The aim of the study is to evaluate the effect of a caffeine supplement on the stimulation of lipolysis and the production of ketones in healthy adults (N=10). Two different doses of caffeine (2.5 mg/kg of BW and 5 mg/kg of BW) are compared. All the participants have to follow three sequential visits of four hours each, which included a breakfast with one of the doses (2.5 or 5 mg/kg) of the caffeine supplement or without any supplement (baseline) and repeated blood sampling in order to evaluate ketone concentrations.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 10
• Est. completion date: June 2015
• Est. primary completion date: January 2015
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Healthy adults

• 18 years old and over

Exclusion Criteria:

• Drinking more than 300 mg of caffeine per day

• Diabetes or prediabetes

• Abnormal liver and kidney function

• Uncontrolled dyslipidemia, blood pressure

• Use of drugs known to influence the metabolism of lipids and carbohydrates (steroid, beta-blockers, diuretics, insulin sensitizer, etc.)

• Severe inflammation or infection

• Pregnancy

• Smoking

Related Conditions & MeSH terms

• Healthy Adults

Intervention

Dietary Supplement:
• Control
4-hour visit with no caffeine is given during a standardize breakfast follow by repeated blood sampling.
• Caffeine low dose
4-hour visit with a dose of 2.5 mg/kg of caffeine is given during a standardize breakfast follow by repeated blood sampling.
• Caffeine high dose
4-hour visit with a dose of 5 mg/kg of caffeine is given during a standardize breakfast follow by repeated blood sampling.

Locations

Country	Name	City	State
Canada	Research Centre on Aging (CSSS-IUGS - CIUSSS de l'Estrie - CHUS)	Sherbrooke	Quebec

Sponsors (1)

Lead Sponsor	Collaborator
Université de Sherbrooke

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Plasma Acetoacetate Concentrations	Plasma acetoacetate (µmol/L) measured over a 4 hour period.	4 hours
Primary	Plasma Beta-hydroxybutyrate Concentrations	Plasma beta-hydroxybutyrate (µmol/L) measured over a 4 hour period.	4 hours
Secondary	Plasma Glucose Concentrations	Plasma glucose (mmol/L) measured over a 4 hour period.	4 hours
Secondary	Plasma Cholesterol Concentrations	Plasma cholesterol (mmol/L) measured over a 4 hour period.	4 hours
Secondary	Plasma Triglyceride Concentrations	Plasma triglycerides (mmol/L) measured over a 4 hour period.	4 hours